An observational study in Early Stage Breast Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Jonsson Comprehensive Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Jonsson Comprehensive Cancer Center.
Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, this one is one of 2 that started in 2024, is one of 3 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 43rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Jonsson Comprehensive Cancer Center · Sites in United States
Women only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 40–80 · Healthy volunteers
Jonsson Comprehensive Cancer Center · Sites in United States
Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 16 · Phase 3 2 · Phase 4 2
First in 1997; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 42 across the 37 interventional studies, 27 across the 3 observational. Of the 30 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jonsson Comprehensive Cancer Center is the lead sponsor of 398 studies on the registry; 66 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.
5 of the studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06387173Jonsson Comprehensive Cancer CenterRegistry of Patients Undergoing Cryoablation for Early Stage Breast Cancer | 2027-01-03 |
| NCT04297020Jonsson Comprehensive Cancer CenterBrain Health in Breast Cancer Survivors | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
| NCT05595499Jonsson Comprehensive Cancer CenterFisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | 2027-08-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.
PRIMARY OBJECTIVE:
I. To obtain observational real-life data of patients who choose this non-conventional treatment and to follow their outcomes.
OUTLINE: This is an observational study.
Patients have their medical records reviewed on study.
Patients undergoing cryoablation for breast cancer
Inclusion Criteria:
Patients have their medical records reviewed on study.
Other: Non-Interventional Study
Non-interventional study
Prospectively track patients who undergo cryoablation for breast cancer and record post-treatment related events.
record follow up of symptoms, reported complications, breast imaging findings, and results of any future biopsies related to cancer, and treatment of breast cancer.
Time frame: five years from last participant enrollment
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 35 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jonsson Comprehensive Cancer Center →